Literature DB >> 8100519

A role for neuropeptide-Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation.

P D Lambert1, J P Wilding, A A al-Dokhayel, C Bohuon, E Comoy, S G Gilbey, S R Bloom.   

Abstract

A marked increase in food intake is observed in the rat after central injection of neuropeptide-Y (NPY), dynorphin, or noradrenaline (NA). Levels of both NPY and dynorphin are increased in the hypothalamus of food-deprived rats. The aim of this study was to explore the role of NPY, dynorphin, and NA in the central control of feeding after a period of food deprivation. We have investigated the effect of intracerebroventricular injection of a monoclonal antibody to NPY (NPYAb), a potent and selective kappa-opioid receptor antagonist norbinaltorphimine (norBNI), and the alpha-adrenergic antagonist phentolamine on fast-induced food intake. In animals provided with food after a 24-h fast, NPYAb given 10 min before presentation of food reduced food intake by 30% (P < 0.01) compared to that of animals pretreated with an antibody to chloroquine. A similar (34%; P < 0.05) reduction in fast-induced feeding occurred after pretreatment with norBNI. If norBNI was given together with NPYAb, then a reduction of 51% (P < 0.05) was observed. Pretreatment with phentolamine reduced fast-induced food intake by 39% (P < 0.05), with no evidence of an additive effect when phentolamine was given together with NPYAb. These data would support a role for endogenous NPY, dynorphin, and NA in the mediation of fast-induced feeding. NPY would seem to act independently of dynorphin, but through the same mechanism as NA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100519     DOI: 10.1210/endo.133.1.8100519

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

Review 1.  [Pathophysiology of catabolism in undernurished elderly patients].

Authors:  D Baez-Franceschi; J E Morley
Journal:  Z Gerontol Geriatr       Date:  1999-07       Impact factor: 1.281

2.  Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations.

Authors:  G Magnati; A Dei Cas
Journal:  Eat Weight Disord       Date:  2000-09       Impact factor: 4.652

3.  Neuropeptide Y in central control of feeding and interactions with orexin and leptin.

Authors:  M Niimi; M Sato; T Taminato
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

4.  kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Authors:  C C Chao; G Gekker; S Hu; W S Sheng; K B Shark; D F Bu; S Archer; J M Bidlack; P K Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Neuropeptide-Y in the paraventricular nucleus increases ethanol self-administration.

Authors:  S P Kelley; M A Nannini; A M Bratt; C W Hodge
Journal:  Peptides       Date:  2001-03       Impact factor: 3.750

6.  Effect of food restriction on cocaine locomotor sensitization in Sprague-Dawley rats: role of kappa opioid receptors.

Authors:  Craig P Allen; Yan Zhou; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2012-12-02       Impact factor: 4.530

7.  Neurotensin and dynorphin Bi-Directionally modulate CeA inhibition of oval BNST neurons in male mice.

Authors:  C P Normandeau; M L Torruella Suárez; P Sarret; Z A McElligott; E C Dumont
Journal:  Neuropharmacology       Date:  2018-09-21       Impact factor: 5.250

8.  High-affinity neuropeptide Y receptor antagonists.

Authors:  A J Daniels; J E Matthews; R J Slepetis; M Jansen; O H Viveros; A Tadepalli; W Harrington; D Heyer; A Landavazo; J J Leban; A Spaltenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

9.  High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity.

Authors:  Jinghua Lu; Peter D Sun
Journal:  bioRxiv       Date:  2020-07-01

10.  Glutamate and GABA in Appetite Regulation.

Authors:  Teresa C Delgado
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-15       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.